Kristi Rosa

Findings from the phase 2 AVATAR trial suggest stereotactic ablative body radiotherapy may postpone the use of systemic therapy, offering patients with ER-positive/HER2-negative metastatic breast cancer another option.

Datopotamab deruxtecan delivered promising responses in patients with heavily pretreated non–small cell lung cancer with actionable genomic alterations.

Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.

IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.

Data from a subgroup of patients with EGFR-mutated non–small cell lung cancer showed that an experimental treatment strategy using durvalumab and chemotherapy is not beneficial for patients.

Phase 3 ETER701 study results reveal the benefit of adding benmelstobart to the standard combination of anlotinib and chemotherapy.

Following positive results from the phase 1/2 EPCORE NHL-1 trial, epcoritamab is currently under evaluation across different lines of therapy and in various combinations for diffuse large B-cell lymphoma.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Further dose optimization is ongoing in the phase 1 study of BI 764532 following the read-out of positive results.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

According to follow-up data from EMPOWER-Lung 3, cemiplimab plus platinum-doublet chemotherapy maintained clinically improvements in advanced non–small cell lung cancer.

Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

High-dose IL-2 is approved for use as a single agent in patients with metastatic melanoma. However, the agent induces limited efficacy and is known to have considerable toxicity.

Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.

At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.

While JCAR021 showed durable responses, there was a high rate of neurotoxicity when given at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma.

In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.

In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.

SWOG 1815, which was investigating nab-paclitaxel plus gemcitabine and cisplatin, has missed its primary end point.

CheckMate-649 study findings continue to support frontline nivolumab and chemotherapy for patients with advanced gastric, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Positive results were shown with ziftomenib monotherapy in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.